A Revolutionary Approach to Cancer Treatment


Jounce Therapeutics, Inc. (NASDAQ: JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial.


Year Invested: 2013
Location: Cambridge, Mass.
Visit: www.jouncetx.com

Recent News

January 3, 2018
Jounce Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

December 14, 2017
Jounce Therapeutics Added to NASDAQ Biotechnology Index

December 7, 2017
Jounce Therapeutics to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner

Cary Pfeffer, M.D.
Partner

Robert Kamen, Ph.D.
Venture Partner